{"doi":"10.1056/nejmoa1611618","title":"Trial of Cannabidiol for Drug-Resistant Seizures in the Dravet Syndrome","abstract":null,"journal":"New England Journal of Medicine","year":2017,"id":687365,"datarank":1.1150499810249255,"base_score":7.433666540166168,"endowment":7.433666540166168,"self_citation_contribution":1.1150499810249255,"citation_network_contribution":0.0,"self_endowment_contribution":1.1150499810249255,"citer_contribution":0.0,"corpus_percentile":null,"corpus_rank":null,"citation_count":1691,"citer_count":0,"citers_with_citation_signal":0,"citers_with_endowment":0,"datacite_reuse_total":25,"is_dataset":false,"is_dataset_confidence":null,"is_data_producer":false,"deposit_databanks":null,"is_oa":false,"file_count":0,"downloads":0,"has_version_chain":false,"published_date":null,"fair_score":null,"fair_percentile":null,"algorithm_id":"datarank_citation_only_1hop_v6","ranking_scope":"data_only","authors":[{"id":52272,"name":"J. Helen Cross","orcid":"0000-0001-7345-4829","position":1,"is_corresponding":false},{"id":463262,"name":"Linda Laux","orcid":"0000-0002-1429-2206","position":2,"is_corresponding":false},{"id":1795700,"name":"Eric Marsh","orcid":null,"position":3,"is_corresponding":false},{"id":880025,"name":"Ian Miller","orcid":"0000-0001-8033-2520","position":4,"is_corresponding":false},{"id":494276,"name":"Rima Nabbout","orcid":"0000-0001-5877-4074","position":5,"is_corresponding":false},{"id":1635476,"name":"Ingrid E. Scheffer","orcid":null,"position":6,"is_corresponding":false},{"id":352796,"name":"Elizabeth A. Thiele","orcid":"0000-0003-3431-4713","position":7,"is_corresponding":false},{"id":1197864,"name":"Stephen Wright","orcid":"0000-0002-8593-6056","position":8,"is_corresponding":false},{"id":241351,"name":"Orrin Devinsky","orcid":"0000-0003-0044-4632","position":0,"is_corresponding":false}],"reference_count":0,"raw_metadata":{"has_enrichment":true,"resolved":true,"title":"Trial of Cannabidiol for Drug-Resistant Seizures in the Dravet Syndrome","abstract":"BACKGROUND: The Dravet syndrome is a complex childhood epilepsy disorder that is associated with drug-resistant seizures and a high mortality rate. We studied cannabidiol for the treatment of drug-resistant seizures in the Dravet syndrome. METHODS: In this double-blind, placebo-controlled trial, we randomly assigned 120 children and young adults with the Dravet syndrome and drug-resistant seizures to receive either cannabidiol oral solution at a dose of 20 mg per kilogram of body weight per day or placebo, in addition to standard antiepileptic treatment. The primary end point was the change in convulsive-seizure frequency over a 14-week treatment period, as compared with a 4-week baseline period. RESULTS: The median frequency of convulsive seizures per month decreased from 12.4 to 5.9 with cannabidiol, as compared with a decrease from 14.9 to 14.1 with placebo (adjusted median difference between the cannabidiol group and the placebo group in change in seizure frequency, -22.8 percentage points; 95% confidence interval [CI], -41.1 to -5.4; P=0.01). The percentage of patients who had at least a 50% reduction in convulsive-seizure frequency was 43% with cannabidiol and 27% with placebo (odds ratio, 2.00; 95% CI, 0.93 to 4.30; P=0.08). The patient's overall condition improved by at least one category on the seven-category Caregiver Global Impression of Change scale in 62% of the cannabidiol group as compared with 34% of the placebo group (P=0.02). The frequency of total seizures of all types was significantly reduced with cannabidiol (P=0.03), but there was no significant reduction in nonconvulsive seizures. The percentage of patients who became seizure-free was 5% with cannabidiol and 0% with placebo (P=0.08). Adverse events that occurred more frequently in the cannabidiol group than in the placebo group included diarrhea, vomiting, fatigue, pyrexia, somnolence, and abnormal results on liver-function tests. There were more withdrawals from the trial in the cannabidiol group. CONCLUSIONS: Among patients with the Dravet syndrome, cannabidiol resulted in a greater reduction in convulsive-seizure frequency than placebo and was associated with higher rates of adverse events. (Funded by GW Pharmaceuticals; ClinicalTrials.gov number, NCT02091375 .).","is_dataset_classified":null,"base_score":7.433666540166168,"endowment":7.433666540166168,"datacite_reuse_total":25,"file_count":0,"downloads":0,"views":0,"has_version_chain":false,"is_dataset":false,"is_oa":false,"pmid":"28538134","pmcid":null,"openalex_id":"https://openalex.org/W2620218661","authors":[],"funders":[{"funder_name":"National Institute for Health Research (NIHR)","grant_id":"NF-SI-0515-10073","title":null}],"total_grants":1,"fwci":116.7422,"citation_percentile":0.99978232,"influential_citations":0,"citation_trend":[{"year":2016,"count":2},{"year":2017,"count":41},{"year":2018,"count":165},{"year":2019,"count":207},{"year":2020,"count":293},{"year":2021,"count":215},{"year":2022,"count":202},{"year":2023,"count":171},{"year":2024,"count":154},{"year":2025,"count":161},{"year":2026,"count":77}],"oa_status":"bronze","license":"other-oa","oa_locations":[{"url":"https://www.nejm.org/doi/pdf/10.1056/NEJMoa1611618?articleTools=true","host_type":"journal"},{"url":"https://www.nejm.org/doi/pdf/10.1056/NEJMoa1611618?articleTools=true","host_type":"publisher"},{"url":"http://www.nejm.org/doi/pdf/10.1056/NEJMoa1611618","host_type":"publisher"},{"url":"https://doi.org/10.1056/nejmoa1611618","host_type":"journal"},{"url":"https://pubmed.ncbi.nlm.nih.gov/28538134","host_type":"repository"},{"url":"https://pubmed.ncbi.nlm.nih.gov/28813226","host_type":"repository"},{"url":"https://discovery.ucl.ac.uk/id/eprint/1558984/","host_type":"repository"},{"url":"http://hdl.handle.net/20.500.11820/2ed5e0db-7de9-4411-93d7-3a5c388006b9","host_type":"repository"},{"url":"https://hdl.handle.net/20.500.11820/2ed5e0db-7de9-4411-93d7-3a5c388006b9","host_type":"repository"},{"url":"https://www.research.ed.ac.uk/en/publications/2ed5e0db-7de9-4411-93d7-3a5c388006b9","host_type":"repository"},{"url":"https://discovery.ucl.ac.uk/1558984/1/Cross_nejmoa1611618.pdf","host_type":"repository"}],"fields_of_study":["Epilepsy research and treatment","Cannabis and Cannabinoid Research","Diet and metabolism studies"],"mesh_terms":["Adolescent","Anticonvulsants","Cannabidiol","Child","Child, Preschool","Double-Blind Method","Epilepsies, Myoclonic","Fatigue","Female","Humans","Liver","Liver Function Tests","Male","Seizures"],"keywords":["Cannabidiol","Dravet syndrome","Medicine","Placebo","Anesthesia","Epilepsy","Confidence interval","Odds ratio","Lennox–Gastaut syndrome","Internal medicine","Pediatrics","Cannabis","Psychiatry"],"sdg_mappings":[{"sdg_number":0,"sdg_label":"Good health and well-being"}],"linked_datasets":[{"doi":"10.6084/m9.figshare.13710521.v1","title":"Additional file 1 of Cannabinoid treatment for autism: a proof-of-concept randomized trial","publisher":"figshare","resource_type":"JournalArticle"},{"doi":"10.6084/m9.figshare.13710521","title":"Additional file 1 of Cannabinoid treatment for autism: a proof-of-concept randomized trial","publisher":"figshare","resource_type":"JournalArticle"},{"doi":"10.6084/m9.figshare.13710524.v1","title":"Additional file 2 of Cannabinoid treatment for autism: a proof-of-concept randomized trial","publisher":"figshare","resource_type":"JournalArticle"},{"doi":"10.6084/m9.figshare.13710524","title":"Additional file 2 of Cannabinoid treatment for autism: a proof-of-concept randomized trial","publisher":"figshare","resource_type":"JournalArticle"},{"doi":"10.6084/m9.figshare.17194168.v1","title":"Additional file 1 of Cannabidiol (CBD) Use among children with juvenile idiopathic arthritis","publisher":"figshare","resource_type":"JournalArticle"},{"doi":"10.6084/m9.figshare.17194168","title":"Additional file 1 of Cannabidiol (CBD) Use among children with juvenile idiopathic arthritis","publisher":"figshare","resource_type":"JournalArticle"},{"doi":"10.6084/m9.figshare.18230843.v1","title":"Additional file 1 of A mixed methods analysis of cannabis use routines for chronic pain management","publisher":"figshare","resource_type":"JournalArticle"},{"doi":"10.6084/m9.figshare.18230843","title":"Additional file 1 of A mixed methods analysis of cannabis use routines for chronic pain management","publisher":"figshare","resource_type":"JournalArticle"},{"doi":"10.6084/m9.figshare.18230846.v1","title":"Additional file 2 of A mixed methods analysis of cannabis use routines for chronic pain management","publisher":"figshare","resource_type":"JournalArticle"},{"doi":"10.6084/m9.figshare.18230846","title":"Additional file 2 of A mixed methods analysis of cannabis use routines for chronic pain management","publisher":"figshare","resource_type":"JournalArticle"},{"doi":"10.6084/m9.figshare.20064224","title":"Additional file 1 of Healthcare provider and medical cannabis patient communication regarding referral and medication substitution: the Canadian context","publisher":"figshare","resource_type":"JournalArticle"},{"doi":"10.6084/m9.figshare.20064224.v1","title":"Additional file 1 of Healthcare provider and medical cannabis patient communication regarding referral and medication substitution: the Canadian context","publisher":"figshare","resource_type":"JournalArticle"},{"doi":"10.6084/m9.figshare.20517164.v1","title":"Additional file 1 of Medical cannabinoids: a pharmacology-based systematic review and meta-analysis for all relevant medical indications","publisher":"figshare","resource_type":"JournalArticle"},{"doi":"10.6084/m9.figshare.20517164","title":"Additional file 1 of Medical cannabinoids: a pharmacology-based systematic review and meta-analysis for all relevant medical indications","publisher":"figshare","resource_type":"JournalArticle"},{"doi":"10.6084/m9.figshare.20517167.v1","title":"Additional file 2 of Medical cannabinoids: a pharmacology-based systematic review and meta-analysis for all relevant medical indications","publisher":"figshare","resource_type":"JournalArticle"},{"doi":"10.6084/m9.figshare.20517167","title":"Additional file 2 of Medical cannabinoids: a pharmacology-based systematic review and meta-analysis for all relevant medical indications","publisher":"figshare","resource_type":"JournalArticle"},{"doi":"10.6084/m9.figshare.20517173.v1","title":"Additional file 3 of Medical cannabinoids: a pharmacology-based systematic review and meta-analysis for all relevant medical indications","publisher":"figshare","resource_type":"JournalArticle"},{"doi":"10.6084/m9.figshare.20517173","title":"Additional file 3 of Medical cannabinoids: a pharmacology-based systematic review and meta-analysis for all relevant medical indications","publisher":"figshare","resource_type":"JournalArticle"},{"doi":"10.6084/m9.figshare.20517176.v1","title":"Additional file 4 of Medical cannabinoids: a pharmacology-based systematic review and meta-analysis for all relevant medical indications","publisher":"figshare","resource_type":"JournalArticle"},{"doi":"10.6084/m9.figshare.20517176","title":"Additional file 4 of Medical cannabinoids: a pharmacology-based systematic review and meta-analysis for all relevant medical indications","publisher":"figshare","resource_type":"JournalArticle"},{"doi":"10.6084/m9.figshare.20517179.v1","title":"Additional file 5 of Medical cannabinoids: a pharmacology-based systematic review and meta-analysis for all relevant medical indications","publisher":"figshare","resource_type":"JournalArticle"},{"doi":"10.6084/m9.figshare.20517179","title":"Additional file 5 of Medical cannabinoids: a pharmacology-based systematic review and meta-analysis for all relevant medical indications","publisher":"figshare","resource_type":"JournalArticle"},{"doi":"10.6084/m9.figshare.20517185.v1","title":"Additional file 6 of Medical cannabinoids: a pharmacology-based systematic review and meta-analysis for all relevant medical indications","publisher":"figshare","resource_type":"JournalArticle"},{"doi":"10.6084/m9.figshare.20517185","title":"Additional file 6 of Medical cannabinoids: a pharmacology-based systematic review and meta-analysis for all relevant medical indications","publisher":"figshare","resource_type":"JournalArticle"},{"doi":"10.6084/m9.figshare.21628813.v1","title":"Additional file 1 of A randomized, controlled trial of ZYN002 cannabidiol transdermal gel in children and adolescents with fragile X syndrome (CONNECT-FX)","publisher":"figshare","resource_type":"JournalArticle"}],"clinical_trials":[],"software_tools":[],"database_accessions":[{"name":"nct"}],"source":"live","citation_network_status":"fetched"},"created_at":"2026-08-18T21:51:11.885988Z","pmid":null,"pmcid":null,"fwci":null,"citation_percentile":null,"influential_citations":0,"oa_status":null,"license":null,"views":0,"total_file_size_bytes":0,"version_count":0,"fair_f":null,"fair_a":null,"fair_i":null,"fair_r":null,"fair_zscore":null,"fair_rationale":null,"fair_model":null,"fair_agent_version":null,"fair_fulltext_source":null,"fair_has_llm":null,"fair_computed_at":null,"clinical_trials":[],"software_tools":[],"db_accessions":[],"linked_datasets":[],"topics":[]}